drugset
drugset / Trial / NCT07274761

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

NCT07274761 ↗

Phase 2 Active not recruiting 24 enrolled Shanghai Pulmonary Hospital, Shanghai, China
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).

Timeline

Start
2024-10-17
Primary completion
2030-05-01
Completion
2030-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunvozertinib Small molecule 300 mg Oral

Indications

non-small cell lung carcinoma